Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 11.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.0%)
  • Dividend yield for the last twelve months 1.7%
  • Free cash flow yield 0.6% (LTM)
  • Share price is 49.1% higher than minimum and 4.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (28.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.3 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (0.0%)134.44
year average price 121.30  


year start price 104.02 2024-07-06

min close price 100.07 2024-07-18

max close price 140.22 2025-03-03

current price 134.44 2025-07-05
Common stocks: 1 746 881 140

Dividend Yield:  1.7%
FCF Yield LTM: 0.6%
EV / LTM EBITDA: 28.5x
EV / EBITDA annualized: 29.8x
Last revenue growth (y/y):  +4.0%
Last growth of EBITDA (y/y):  +18.0%
Historical revenue growth:  -1.2%
Historical growth of EBITDA:  -6.7%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 234 851
Net Debt ($m): 6 667
EV (Enterprise Value): 241 518
EBITDA LTM ($m): 8 475
EV / LTM EBITDA: 28.5x
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-02zacks.com

Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion

2025-07-02zacks.com

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

2025-06-30seekingalpha.com

Abbott Labs: Proactive, Adaptive, Solid

2025-06-26zacks.com

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

2025-06-24seekingalpha.com

Best Dividend Kings: June 2025

2025-06-20prnewswire.com

New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

2025-06-19zacks.com

ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?

2025-06-13prnewswire.com

Abbott Declares 406th Consecutive Quarterly Dividend

2025-06-13247wallst.com

5 Dividend Kings Are Delivering Massive Total Returns of Up to 34% This Year

2025-06-05zacks.com

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data